L Huang, Y Li, Y Du, Y Zhang, X Wang, Y Ding… - Nature …, 2019 - nature.com
One of the main challenges for immune checkpoint blockade antibodies lies in malignancies
with limited T-cell responses or immunologically “cold” tumors. Inspired by the capability of …